You are here
A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.
A total of 28 patients received open-label tocilizumab for 96 weeks.
The median glucocorticoid dose was 0.223 mg/kg/day at study entry; 0.131 mg/kg/day after 48 weeks; and 0.105 mg/kg/day after 96 weeks.
Overall, 46.4% of patients reduced their dose to <0.1 mg/kg/day, which was less than half the dose administered at relapse before study entry
Using imaging studies patients’ disease either was improved (17.9%) or stable (67.9%) after 96 weeks.
No unexpected safety issues were reported.